GlassScriptPhysician profile
Siva Gummadi
NPI 1063448488
$17,917.84
in general payments reported to CMS, 2019-2025
41 companies · $5,327 in 2025
The $5,327 reported for 2025 was more than what 84% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $711 · 2021: $2,738 · 2022: $2,827 · 2023: $2,379 · 2024: $2,865 · 2025: $5,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,247 · Consulting Fee: $3,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,246.98 |
| Consulting Fee | $3,324.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $3,415.59 | 2022-2025 | |
| Angiodynamics, INC. | $1,889.90 | 2021-2025 | Auryon Laser System 100-120 Vac |
| Janssen Pharmaceuticals, INC | $1,712.49 | 2019-2024 | Xarelto |
| Cook Medical LLC | $1,274.61 | 2019-2025 | Zilver Ptx, Zenith Alpha, Icast Covered Stent System, 6mmx22mmx120cm |
| Boston Scientific Corporation | $1,244.69 | 2020-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
| Pfizer INC. | $1,097.18 | 2019-2025 | |
| Amgen INC. | $843.22 | 2020-2025 | Repatha, Repatha |
| Abbott Laboratories | $727.27 | 2019-2025 | Aveir, Jot Dx, Mitraclip |
| Novartis Pharmaceuticals Corporation | $683.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.85 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $423.59 | 2021-2025 | Verquvo |
| Philips North America LLC | $382.37 | 2022-2025 | Ecc Solutions, Mcot, (Ck4) Mcot |
| Medtronic, INC. | $343.56 | 2021-2025 | Onyx Frontier, Turbohawk |
| E.R. Squibb & Sons, L.L.C. | $317.46 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $305.63 | 2019-2025 | Lifevest |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $290.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $286.12 | 2019-2025 | Lokelma, Bevespi Aerosphere, Andexxa |
| Impulse Dynamics (USA) INC. | $277.49 | 2021-2025 | Optimizer |
| Kestra Medical Technology Services, INC. | $225.30 | 2023-2025 | Assure Wcd |
| Veryan Medical Incorporated | $202.68 | 2022-2023 | Biomimics 3d Vascular Stent System |
| Biotronik INC. | $191.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $184.09 | 2019-2022 | |
| Cvrx, INC. | $143.29 | 2021-2024 | Barostim Neo System |
| Silk Road Medical, INC. | $133.11 | 2020 | |
| Stryker Corporation | $124.78 | 2021 | |
| Penumbra, INC. | $119.56 | 2024 | Penumbra System |
| Atricure, INC. | $83.03 | 2023-2024 | |
| Astellas Pharma US INC | $63.05 | 2019-2020 | |
| Amarin Pharma, INC. | $56.31 | 2020-2022 | |
| Cardiovascular Systems INC. | $42.82 | 2019-2022 | |
| Elutia, INC. | $42.63 | 2022-2024 | Ecm Patch,Pouch |
| Abiomed | $39.39 | 2025 | |
| Esperion Therapeutics, INC. | $38.87 | 2021-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $37.62 | 2019 | |
| Bardy Diagnostics, INC. | $37.50 | 2019-2022 | |
| Novo Nordisk INC | $32.18 | 2021-2023 | Ozempic |
| Edwards Lifesciences Corporation | $24.13 | 2022 | |
| Bard Peripheral Vascular, INC. | $20.05 | 2025 | Lutonix Drug Coated Balloon |
| Lexicon Pharmaceuticals, INC. | $19.81 | 2023 | Inpefa |
| Tactile Systems Technology INC | $18.70 | 2025 | Flexitouch Plus, Nimbl |
| Lundbeck LLC | $17.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siva Gummadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.